ASO Author Reflections: EMC3 in HCC—A Novel Regulator of PI3K/AKT/mTOR Signaling and Tumor Immunity
Authors:
- 27 October 2025
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2218-2219
Abstract
No abstract availableFunding Information
- Joint Construction Project of Medical Science and Technology of Henan Province (LHGJ20220316)
- Liver and Biliary Mutual Aid Fund of Henan Province Charity Federation (GDXZ2019003)
- the project of the Department of Education of Henan Province (SB201904006)
This publication has 4 references indexed in Scilit:
- EMC3 as a Novel Biomarker and Driver of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma ProgressionAnnals of Surgical Oncology, 2025
- Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for cliniciansCA: A Cancer Journal for Clinicians, 2025
- Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosisCytokine & Growth Factor Reviews, 2024
- The Function, Structure, and Origins of the ER Membrane Protein ComplexAnnual Review of Biochemistry, 2022